Phase II Study of Regorafenib as Maintenance Therapy

NCT03793361 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

127

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Soft Tissue Sarcoma

Interventions

DRUG: Regorafenib
DRUG: Placebo

Sponsor

Centre Oscar Lambret